ID
Disease Name
model type
LPCB-01335
72
lung cancer
Lung adenocarcinoma
pT1cN0
Left Upper Lung
Invasive adenocarcinoma of lung (acinar type 50%, papillary type 30%, lepidic type 20%; IASLC grade 2).
2# tumor cells CK7(+) TTF-1(+) NapsinA(+) Ki-67(about 2%+) P40(-) CDX-2(-) Brg-1(+) PSA(-) 1# 6# elastic fiber stain no tumor invasion of elastic fiber layer pathological stage pT1cN0 9th edition AJCC/UICC
No medication
Osimertinib:0.741; Gefitinib:0.41; Afatinib<0.02; Cisplatin+Paclitaxel>74.4
(Lung cancer - organoid) Epithelioid cells arranged partially in glands and focally in nested clusters, expressing only CK7 by IHC: CK7(+), TTF-1(-), P40(-), Ki-67(+, 60%).
DPYD,PHGDH,PSMB4,POGZ,EDAR,OBSL1,ECEL1,WDR6,SCD5,PKHD1,PKHD1,SYNE1,GATA4,ROR2,DCHS1,ABCC8,PDHX,B3GAT3,MTHFD1,GALC,CTD-2524L6.3,ANKRD11,MC1R,TP53,TP53,INSR,LDLR,LDLR,ACP5,GCDH,SLC4A11,COL6A1,TCN2
PDO
登录后
LPCB-01333
53
Cervical Cancer
Cervical Squamous Cell Carcinoma， CSCC
IB
Specimen of Extensive Hysterectomy and Bilateral Adnexa + Pelvic Lymph Node Dissection, Tumor Location: External Os of Cervix
Specimen: Radical hysterectomy, bilateral adnexa, pelvic lymphadenectomy. Tumor location: ectocervix. Gross type: exophytic. Size: 3.3×3.3×0.2 cm. Histologic type: non-keratinizing squamous cell carcinoma, moderately to poorly differentiated. Early stromal invasion (depth 1 mm). Lymphovascular invasion (-). Endocervix involved; lower uterine segment, vaginal wall, margins, parametria, adnexa free of tumor. Endometrium: proliferative. Lymph nodes: 0/30 negative. IHC: MMR intact, AE1/AE3+, CD31-, D2-40-, Syn-, CK7+.
PMS2(+) MSH2(+) MLH1(ES05)(+) MSH6(+) AE1/AE3+CD31(-) AE1/AE3+D2-40(-) Syn(-) CK7(+)
No medication
Paclitaxel:38.88; Cisplatin:16.13; Nectin>100
(Cervical cancer - organoid) Epithelioid cells distributed in nests and small clusters identified, consistent with squamous cell carcinoma origin by IHC: P40(+), P63(+), CK7(+), Ki-67(+, 70%).
LMNA,FYCO1,ACAD9,CLRN1,CNGA1,FBXW7,SYNE1,BRAT1,PGAM2,GATA4,WRN,ENG,ASS1,RBM20,HRAS,GALC,CTD-2524L6.3,VPS33B,TCAP,TUBB4A,DOCK6,DNMT3B,WNT7B
PDO
登录后
LPCB-01332
71
Ovarian Cancer
Ovarian Endometrioid Adenocarcinoma，OEC
IIIC
Subextensive Hysterectomy and Bilateral Adnexa + Pelvic Peritoneum + Pelvic Mass + Part of Greater Omentum; Greater Omentum; Ileocecal Tumor; Appendix; Sigmoid Mesentery Nodule
Specimen: Radical hysterectomy, bilateral adnexa, pelvic peritoneum, pelvic mass, partial omentum, omentum, ileocecal tumor, appendix, mesosigmoid nodule. Laterality: left adnexa. Histologic type: poorly differentiated carcinoma, pending IHC for classification. Right tube free of tumor. Endometrium: atrophic. Cervix: chronic inflammation; adenomyosis. Peritoneal, omental, ileocecal, and mesosigmoid lesions involved by carcinoma. Chronic appendicitis with lymphovascular embolus. Supplemental diagnosis: (Left adnexa) endometrioid carcinoma, grade III. IHC: ER-, PR-, P53 70% cytoplasmic positivity (suggestive of mutation), HER2 1+, P16 diffuse +, MMR intact, PD-L1 CPS=15.
ER(-) PR(-) p53(70% cytoplasmic moderate positive nuclear negative suggesting possible mutation molecular testing recommended) HER2(1+) p16(diffuse +) MLH1(M1)(partial +/unsatisfactory molecular testing recommended) MSH2(+) MSH6(+) PMS2(+) PD-L1(22C3) CPS=15
No medication
Paclitaxel:0.89; Carboplatin:512.90; Gemcitabine<3.80
(Ovarian cancer - organoid) Epithelioid cells distributed in glands identified. IHC: CK7(+), WT-1(-), P53(+, wild type), Ki-67(+, 80%).
ALPL,SLC2A1,CNGA3,MERTK,TTN,SCN5A,TREX1,ILDR1,CASR,SLC7A14,FAM175A,POLR1C,PLG,GATA4,PLEC,CDKN2A,LAMC3,INPP5E,ALDH18A1,PYGM,KRAS,GJB2,BRCA2,CA12,KBTBD13,CTD-2524L6.3,CACNA1H,SERPINB7,LDLR,RYR1,RUNX1,TNFRSF13C,IL2RG,MED12
PDO
登录后
LPCB-01294
49
Ovarian Cancer
Ovarian Endometrioid Adenocarcinoma，OEC
T3cN0M0
Right Umbilical Mass
(Bilateral adnexa) Carcinoma consistent with endometrioid carcinoma, G3 by immunohistochemistry; no definite lymphovascular or neural invasion. (Total uterus) proliferative endometrium; chronic cervicitis; multiple leiomyomas. (Right ovarian adhesive tissue, greater omentum, bilateral hemidiaphragm, ligamentum teres hepatis, rectal mesentery, liver surface mass, lesser omentum, right umbilicus, rectal wall, right rectal peritoneum, right colovesical peritoneum) involved by carcinoma. (Appendix) chronic inflammation, no malignancy.
A17 CR(+) Vim(-) Ki-67 80%(+) ER 60% weak(+) PR(-) Pax-8(+) p53(+)/mutant p16 mottled(+) PD-L1(clone 22C3) CPS=1 C-erbB-2(0) MLH1(+) MSH2(+) MSH6(+) PMS2(+)
No medication
Paclitaxel>38.88; Carboplatin:27.31; Gemcitabine:20.70
(Ovarian cancer - organoid) Epithelioid cells arranged in glands, consistent with ovarian origin by IHC and homologous comparison: CA125(-/+), WT-1(-), ER(-), P53(+, wild type).
MTOR,CPT2,BAP1,ARL6,SLC7A14,PDE6B,DNAH5,DNAH5,AARS2,COG5,GATA4,EYA1,PEX2,CYP11B1,GNE,RBP4,NFKB2,SCYL1,PCCA,GALC,DICER1,CTD-2524L6.3,PKD1,DHODH,MC2R,GCDH,RYR1,APOE,ADA,UPB1,BTK
PDO
登录后
LPCB-01293
55
Ovarian Cancer
Ovarian Endometrioid Adenocarcinoma，OEC
II
Subextensive Hysterectomy + Bilateral Adnexa + Giant Pelvic Mass + Anterior Rectal Tumor
Specimen: Total uterus, bilateral adnexa, appendix, omentum, peritoneum. Tumor size: left 2.5×2×1.5 cm; right 1.8×1×1 cm. Laterality: bilateral ovaries. Histologic type: high-grade serous carcinoma. Tubes, endometrium, cervix, myometrium, peritoneum, omentum, bowel wall involved. Lymph node metastasis: left pelvic 1/2, right common iliac 1/1, right pelvic 4/4, retroportal 2/2. IHC: PD-L1 CPS=15.
ER(partial +) PR(partial +) p53(focal + wild type) HER2(0) p16(mottled +) MLH1(M1)(partial -) MSH2(+) MSH6(+) PMS2(+) 尾-catenin(membrane +) PTEN(partial +) PAX8(+) PRAME(faintly positive) WT1(-)
No medication
Paclitaxel>38.88; Carboplatin:238.6; Gemcitabine:117.80
(Ovarian cancer - organoid) Epithelioid cells consistent with endometrioid carcinoma by IHC and homologous comparison: Pax-8(+/-), CA125(+), WT-1(-), ER(-/+), Ki-67(+, 40%).
MTHFR,MFN2,ATP13A2,SNIP1,HPDL,MSTO1,FLVCR1,PXDN,CNGA3,BCS1L,CHRNG,AGXT,D2HGDH,CTNNB1,WDR6,MYLK,GATA2,PIK3CA,FRAS1,EYS,RFX6,GATA4,FGFR1,MADD,EFEMP2,ATM,KRAS,POLE,SACS,GALC,CTD-2524L6.3,HBA1,ASPA,GUCY2D,FOXN1,PCGF2,DCC,MAP2K2,HNF4A,DYRK1A,DYRK1A,MLC1,COL4A5
PDO
登录后
LPCB-01292
49
Ovarian Cancer
High-Grade Serous Ovarian Carcinoma
ⅢC
Specimen of Total Hysterectomy + Bilateral Adnexa + Appendix + Greater Omentum + Multiple Pelvic and Abdominal Lesions
Invasive adenocarcinoma of lung (papillary 40%, acinar 30%, lepidic 25%, micropapillary 5%; IASLC grade 2).
Immunohistochemical results PD-L1(22C3) CPS 15
No medication
Paclitaxel>38.88; Carboplatin:458.8; Gemcitabine>243.04
(Ovarian cancer - organoid) Epithelioid cells arranged in glands and nested clusters, consistent with ovarian serous epithelial origin by IHC: P53(+), Pax-8(+), WT-1(focal +), Ki-67(+, 50%).
SDCCAG8,TTN,BRPF1,LEPREL1,OXCT1,SGCD,PLG,BRAT1,AP4M1,CFTR,GATA4,TJP2,KCNT1,GRIN1,PRF1,ECHS1,ZNF408,IL10RA,ATP7B,MYH7,GALC,CTD-2524L6.3,MC1R,SLC4A1,SCN4A,INSR,GCDH,NACC1,KMT2B,IL17RA
PDO
登录后
LPCB-01290
56
lung cancer
Lung adenocarcinoma
pT1cN0
Left Upper Lung
Reactive hyperplasia.
Immunohistochemical markers show 5# tumor cells CK7(+) TTF-1(+) NapsinA(+) Ki-67(about 10%+) Brg-1(+) c-Met(2+) P40(-) CDX-2(-) 3#6# elastic fiber stain tumor does not break through elastic fiber layer pathological stage pT1cN0 9th edition AJCC/UICC
No medication
Osimertinib:0.258; Gefitinib:0.343; Afatinib<0.02; Cisplatin+Paclitaxel:3.826
(Lung cancer - organoid) Epithelioid cells arranged in nested clusters of varying sizes, with partial expression of P40 and partial expression of CK7 by IHC: P40(+/-), CK7(focal +), TTF-1(-), Napsin-A(-).
SLC2A1,HAX1,EPRS,ZBTB18,MSH2,DYSF,ALMS1,CYCTP,COG5,GATA4,ASS1,KCNT1,PRF1,MYO7A,TYR,GALC,CTD-2524L6.3,GAN,SCN4A,GYS1,SEC23B,CBS,MSN,GJB1
PDO
登录后
LPCB-01287
63
lung cancer
NA
None
Anterior & Medial Basal Segment of Right Lower Lobe, No.11 LN
Malignant gastric antral tumor (pT4N2M0, IIIB).
None
No medication
Osimertinib:0.81; Gefitinib:0.6879; Afatinib:0.032; Cisplatin+Paclitaxel:1.945
(Lung cancer - organoid) Epithelioid cells distributed in clusters identified, showing partial glandular differentiation and partial squamous differentiation by IHC: CK7(+), TTF-1(-/+), P40(+/-), Ki-67(+, 30%).
LEPRE1,MSH2,PROC,ERBB4,EVC,FAM175A,AMACR,GATA4,POMT1,KCNT1,SLC34A3,VCL,SCYL1,CTD-2524L6.3,RAD51D,KRT9,ACOX1,MC2R,LDLR,COL18A1,UPB1,ARSE,L1CAM
PDO
登录后
LPCB-01271
69
Gastric Cancer
adenocarcinoma
pT4N2
Lesser Curvature of Gastric Antrum
Malignant rectal tumor.
MSH2(+) MSH6(+) MLH-1(+) PMS-2(+) suggest microsatellite stability MSS Immunohistochemical staining results S-100(nerve fibers +) Her-2(1+) p53(+ 70%) Ki-67(+ 80%) stromal lymphovascular tumor emboli(+) detected by CD31 and D2-40
No medication
Oxaliplatin:3.62; 5-FU>29.36; Olaparib>108.64
(Gastric cancer - organoid) Epithelioid cells consistent with gastric origin by IHC, and consistent with adenocarcinoma by homologous comparison. IHC: CAM5.2(+), MUC-1(+), P53(+, wild type), Ki-67(+, 80%).
ABCB11,TTN,APC,COL12A1,GATA4,ANK1,KAT6B,C2CD3,MVK,MYH7,GALC,CTD-2524L6.3,CDH1,BRCA1,RNF213,TUBB4A,LDLR,LDLR,SLC12A5,DEPDC5
PDO
登录后
LPCB-01256
49
Colorectal Cancer
Rectal Cancer
ⅢB
Rectum
Malignant rectal tumor with incomplete intestinal obstruction.
Tumor cells CK8/18(+) CK20(+) Syn(-) CgA(-) Ki-67: approximately 75%(+) TP53: approximately 95%(+) MLH1(+) MSH2(+) MSH6(+) PMS2(+) Her2:399957-2:3+ 399957-3:3+ Stroma D2-40 lymphatic endothelium(+) CD34 vascular endothelium(+) 399957-2 lymphatic invasion identified no definite vascular tumor emboli Nerve tumor invasion identified
No medication
Oxaliplatin>3.136 ; 5-FU 3.533 ; Regorafenib 1.861
(Colorectal cancer - organoid) Epithelioid cells arranged in glands of varying sizes; cancer cell proportion: 100%.
NLRP3,EDAR,COL6A3,MITF,ENPP1,SLC26A4,GATA4,PLEC,DFNB31,LDB3,SMPD1,HMBS,KRAS,GALC,CTD-2524L6.3,GNPTG,MLYCD,FANCA,TP53,ALDH3A2,MEGF8,JAG1,TP53RK,SLC2A10
PDO
登录后
Reprogramming Cells, Empowering Medicine
©2026 PreceDo Biotechnology Co., Ltd. Powered by：www.300.cn